Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Oct;68(4):681–683. doi: 10.1038/bjc.1993.409

The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.

L D Skarsgard 1, M W Skwarchuk 1, A Vinczan 1, D J Chaplin 1
PMCID: PMC1968590  PMID: 8398693

Abstract

We have observed that low pH can substantially potentiate the cytotoxic effect of the bioreductive drug SR4233 in aerobic HT-29 human tumour cells. No such potentiation was observed under hypoxic conditions. This pH effect might be relevant both to the therapeutic effectiveness and to the normal tissue toxicity of this new agent.

Full text

PDF
681

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker M. A., Zeman E. M., Hirst V. K., Brown J. M. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 1988 Nov 1;48(21):5947–5952. [PubMed] [Google Scholar]
  2. Braunschweiger P. G., Jones S. A., Johnson C. S., Furmanski P. Interleukin-1 alpha-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):369–372. doi: 10.1080/09553009114552171. [DOI] [PubMed] [Google Scholar]
  3. Brown J. M., Lemmon M. J. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):457–461. doi: 10.1016/0360-3016(91)90057-b. [DOI] [PubMed] [Google Scholar]
  4. Chaplin D. J., Durand R. E., Olive P. L. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1279–1282. doi: 10.1016/0360-3016(86)90153-7. [DOI] [PubMed] [Google Scholar]
  5. Chaplin D. J., Olive P. L., Durand R. E. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res. 1987 Jan 15;47(2):597–601. [PubMed] [Google Scholar]
  6. Edwards H. S., Bremner J. C., Stratford I. J. Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):373–377. doi: 10.1080/09553009114552181. [DOI] [PubMed] [Google Scholar]
  7. Herman T. S., Teicher B. A., Coleman C. N. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo. Cancer Res. 1990 Aug 15;50(16):5055–5059. [PubMed] [Google Scholar]
  8. Laderoute K., Wardman P., Rauth A. M. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233). Biochem Pharmacol. 1988 Apr 15;37(8):1487–1495. doi: 10.1016/0006-2952(88)90010-x. [DOI] [PubMed] [Google Scholar]
  9. Sun J. R., Brown J. M. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Res. 1989 Oct 15;49(20):5664–5670. [PubMed] [Google Scholar]
  10. Tocher J. H., Virk N. S., Edwards D. I. DNA damaging effects and voltammetric studies on the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR4233, as a function of pH. Biochem Pharmacol. 1990 Sep 15;40(6):1405–1410. doi: 10.1016/0006-2952(90)90410-m. [DOI] [PubMed] [Google Scholar]
  11. Zeman E. M., Brown J. M., Lemmon M. J., Hirst V. K., Lee W. W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1239–1242. doi: 10.1016/0360-3016(86)90267-1. [DOI] [PubMed] [Google Scholar]
  12. Zeman E. M., Brown J. M. Pre- and post-irradiation radiosensitization by SR 4233. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):967–971. doi: 10.1016/0360-3016(89)90897-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES